Clinical Trial: A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Study Status: Completed
Recruit Status: RECRUITING
Condition: Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
Study Type: INTERVENTIONAL
Official Title: A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy With Immuno-oncology Therapy for Children and Adults With Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
Brief Summary:
This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stage I and II classical Hodgkin lymphoma.Brentuximab vedotin is in a class of medications called antibody-drug conjugates.It is made of a monoclonal antibody called brentuximab that is linked to a cytotoxic agent called vedotin.Brentuximab attaches to CD30 positive lymphoma cells in…
Read more